Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis
-
By
-
Ying-ying Yang
-
Xiao-xue Zeng
-
Xia He
-
Xia-lian Huang
-
Ming-xi Xu
-
Feng-le Mao
-
Yan-qiu Wang
-
Fu-li Qin
-
May 25, 2026
-
Clinical Scorecard: Evaluating the Prognostic Significance of Galectin-3 in Cognitive Impairment: A Comprehensive Review and Meta-Analysis
At a Glance
| Category | Detail |
|---|
| Condition | Cognitive Impairment (CI) |
| Key Mechanisms | Neuroinflammation and vascular injury |
| Target Population | Patients with cognitive impairment, particularly those with vascular risk factors and mild cognitive impairment (MCI) |
| Care Setting | Clinical research and meta-analysis |
Key Highlights
- Peripheral Gal-3 levels are significantly higher in CI patients compared to healthy controls.
- Significant elevation of Gal-3 levels observed in CI with vascular risk factors.
- Gal-3 levels are notably higher in patients with mild cognitive impairment (MCI).
- No significant difference in Gal-3 levels in Alzheimer's disease (AD) patients.
- Evidence suggests Gal-3 may serve as a biomarker for early detection of CI.
Guideline-Based Recommendations
Diagnosis
- Evaluate peripheral Gal-3 levels for potential early detection of cognitive impairment.
Management
- Consider monitoring Gal-3 levels in patients with vascular risk factors.
Monitoring & Follow-up
- Regular assessment of Gal-3 levels may aid in evaluating disease progression.
Risks
- Increased mortality risk associated with cognitive impairment.
Patient & Prescribing Data
Patients with cognitive impairment, especially those with vascular risk factors.
Gal-3 may provide insights into the inflammatory and vascular components of cognitive impairment.
Clinical Best Practices
- Utilize Gal-3 as a biomarker in clinical assessments of cognitive impairment.
- Incorporate vascular risk factor evaluation in cognitive impairment assessments.
Related Resources & Content
